- Home
- NBIX
as 04-04-2025 4:00pm EST
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.
| Founded: | 1992 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 11.0B | IPO Year: | 1996 |
| Target Price: | $164.80 | AVG Volume (30 days): | 1.3M |
| Analyst Decision: | Buy | Number of Analysts: | 21 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 3.29 | EPS Growth: | 33.20 |
| 52 Week Low/High: | $93.59 - $157.98 | Next Earning Date: | 04-30-2025 |
| Revenue: | $2,355,300,000 | Revenue Growth: | 24.81% |
| Revenue Growth (this year): | 15.48% | Revenue Growth (next year): | 16.18% |
Stock Insider Trading Activity of Neurocrine Biosciences Inc. (NBIX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| GORMAN KEVIN CHARLES | NBIX | Director | Feb 13 '25 | Sell | $116.69 | 5,844 | $681,914.46 | 524,209 | |
| SHERWIN STEPHEN A | NBIX | Director | Feb 13 '25 | Sell | $116.69 | 13,831 | $1,613,922.79 | 10,673 | |
| Delaet Ingrid | NBIX | Chief Regulatory Officer | Feb 12 '25 | Sell | $116.71 | 1,471 | $171,674.12 | 4,084 | |
| Lippoldt Darin | NBIX | Chief Legal Officer | Feb 12 '25 | Sell | $116.75 | 2,184 | $254,992.44 | 43,405 | |
| Gano Kyle | NBIX | Chief Executive Officer | Feb 12 '25 | Sell | $116.85 | 2,558 | $298,908.05 | 139,907 | |
| BENEVICH ERIC | NBIX | Chief Commercial Officer | Feb 12 '25 | Sell | $116.73 | 2,154 | $251,427.64 | 43,784 | |
| Boyer David W. | NBIX | Chief Corp. Affairs Officer | Feb 12 '25 | Sell | $116.74 | 1,785 | $208,387.31 | 3,565 | |
| Cooke Julie | NBIX | Chief Human Resources Officer | Feb 12 '25 | Sell | $116.78 | 1,551 | $181,129.15 | 20,190 | |
| ABERNETHY MATT | NBIX | Chief Financial Officer | Feb 12 '25 | Sell | $116.86 | 2,558 | $298,923.22 | 34,775 | |
| Onyia Jude | NBIX | Chief Scientific Officer | Feb 12 '25 | Sell | $116.79 | 2,879 | $336,238.63 | 18,089 |
Latest Neurocrine Biosciences Inc. News
NBIX Breaking Stock News: Dive into NBIX Ticker-Specific Updates for Smart Investing
MT Newswires
2 days ago
Neurocrine Biosciences Appoints New Chief Medical Officer
PR Newswire
3 days ago
Neurocrine Biosciences Appoints Dr. Sanjay Keswani as Chief Medical Officer
MT Newswires
3 days ago
UBS Lowers Price Target on Neurocrine Biosciences to $137 From $154, Keeps Buy Rating
MT Newswires
3 days ago
Deutsche Bank Adjusts Neurocrine Biosciences Price Target to $135 From $138, Maintains Hold Rating
MT Newswires
4 days ago
RBC Trims Price Target on Neurocrine Biosciences to $138 From $139, Keeps Sector Perform Rating
Argus Research
5 days ago
NBIX: Lowering target price to $112.00
PR Newswire
7 days ago
Neurocrine Biosciences Presents Real-World Data on Therapeutic Dose Attainment and Dosing Trends of VMAT2 Inhibitors in Patients With Tardive Dyskinesia
Argus Research
12 days ago
NBIX: Raising target price to $122.00
Compare NBIX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "NBIX Neurocrine Biosciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.